Clinical Trial: NCT05347641
Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma
Status:
NOT YET RECRUITINGPhase:
Phase 2| Lead Sponsor: | The First Affiliated Hospital with Nanjing Medical University |
| Information Provided By: | The First Affiliated Hospital with Nanjing Medical University |
| Last Update Posted: | 2022-04-26 |
Study Overview
Brief Summary
To explore PFS, ORR (CR/CRu+PR), OS and side effects of piamprizumab combined with RMA in newly diagnosed PCNSL, so as to clarify the value of piamprizumab combined with RMA in the first-line treatment of PCNSL patients, and to clarify the clinical and biological factors affecting the efficacy
Official Title
A Single-arm, Prospective, Single-center, Phase II Clinical Study of Penpulimab Combined With RMA in the Treatment of Newly Diagnosed Primary CNS Lymphoma
Conditions
Primary Central Nervous System Lymphoma
Intervention / Treatment
- Drug: Penpulimab
Other Study ID Numbers
- IRB-GL1-AF03
Start Date (Estimated)
2022-06-01
Primary Completion Date (Estimated)
2025-06-01
Study Completion Date (Estimated)
2029-06-01
Enrollment (Estimated)
23
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | The First Affiliated Hospital with Nanjing Medical University |
| Information Provided By: | The First Affiliated Hospital with Nanjing Medical University |
| Last Update Posted: | 2022-04-26 |
Study Overview
Brief Summary
To explore PFS, ORR (CR/CRu+PR), OS and side effects of piamprizumab combined with RMA in newly diagnosed PCNSL, so as to clarify the value of piamprizumab combined with RMA in the first-line treatment of PCNSL patients, and to clarify the clinical and biological factors affecting the efficacy
Official Title
A Single-arm, Prospective, Single-center, Phase II Clinical Study of Penpulimab Combined With RMA in the Treatment of Newly Diagnosed Primary CNS Lymphoma
Conditions
Primary Central Nervous System Lymphoma
Intervention / Treatment
- Drug: Penpulimab
Other Study ID Numbers
- IRB-GL1-AF03
Start Date (Estimated)
2022-06-01
Primary Completion Date (Estimated)
2025-06-01
Study Completion Date (Estimated)
2029-06-01
Enrollment (Estimated)
23
Study Type
Interventional
Phase
Phase 2